The prospective phase 4, open-label study began in January 2023 and includes 500 enrolled participants across the U.S. The medication is a once-a-day pill that treats inflammation caused by inflammatory bowel disease, ulcerative colitis and Chron’s.
According to the report, patients at UG have already begun to experience symptom relief after using the drug.
“I began taking the medication in August,” said Matt Baker, a 34-year-old patient in the trial with ulcerative colitis. “Ultimately, for me, all I’ve seen is an improvement in quality of life.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
